MTA1 and prostate carcinoma: Our serendipitous finding of MTA1 as a new molecular target of resveratrol and its analogs [13, 15] opened opportunities for further pre-clinical validation of the efficacy of pterostilbene as natural epigenetic therapy in prostate cancer.